#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=The present study confirms that a remarkable number of patients with ACC who are operated on with radical intent are destined to relapse .
3-1	15-18	The	abstract[3]	new[3]	coref	6-2[24_3]
3-2	19-26	present	abstract[3]	new[3]	_	_
3-3	27-32	study	abstract[3]	new[3]	_	_
3-4	33-41	confirms	_	_	_	_
3-5	42-46	that	_	_	_	_
3-6	47-48	a	quantity[4]	new[4]	_	_
3-7	49-59	remarkable	quantity[4]	new[4]	_	_
3-8	60-66	number	quantity[4]	new[4]	_	_
3-9	67-69	of	quantity[4]	new[4]	_	_
3-10	70-78	patients	quantity[4]|person	new[4]|new	coref	9-8[53_0]
3-11	79-83	with	quantity[4]	new[4]	_	_
3-12	84-87	ACC	quantity[4]|abstract	new[4]|new	coref	13-12
3-13	88-91	who	_	_	_	_
3-14	92-95	are	_	_	_	_
3-15	96-104	operated	_	_	_	_
3-16	105-107	on	_	_	_	_
3-17	108-112	with	_	_	_	_
3-18	113-120	radical	abstract[7]	new[7]	_	_
3-19	121-127	intent	abstract[7]	new[7]	_	_
3-20	128-131	are	_	_	_	_
3-21	132-140	destined	_	_	_	_
3-22	141-143	to	_	_	_	_
3-23	144-151	relapse	_	_	_	_
3-24	152-153	.	_	_	_	_

#Text=ACC recurrence portends a worse prognosis and has a huge impact on quality of life ; therefore , investigators have considered the use of adjuvant mitotane therapy following surgical operation .
4-1	154-157	ACC	abstract[8]	new[8]	coref	13-12[86_8]
4-2	158-168	recurrence	abstract[8]	new[8]	_	_
4-3	169-177	portends	_	_	_	_
4-4	178-179	a	abstract[9]	new[9]	_	_
4-5	180-185	worse	abstract[9]	new[9]	_	_
4-6	186-195	prognosis	abstract[9]	new[9]	_	_
4-7	196-199	and	_	_	_	_
4-8	200-203	has	_	_	_	_
4-9	204-205	a	abstract[10]	new[10]	coref	16-11[113_10]
4-10	206-210	huge	abstract[10]	new[10]	_	_
4-11	211-217	impact	abstract[10]	new[10]	_	_
4-12	218-220	on	abstract[10]	new[10]	_	_
4-13	221-228	quality	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-14	229-231	of	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-15	232-236	life	abstract[10]|abstract[11]|abstract	new[10]|new[11]|new	_	_
4-16	237-238	;	_	_	_	_
4-17	239-248	therefore	_	_	_	_
4-18	249-250	,	_	_	_	_
4-19	251-264	investigators	person	new	_	_
4-20	265-269	have	_	_	_	_
4-21	270-280	considered	_	_	_	_
4-22	281-284	the	abstract[14]	new[14]	_	_
4-23	285-288	use	abstract[14]	new[14]	_	_
4-24	289-291	of	abstract[14]	new[14]	_	_
4-25	292-300	adjuvant	abstract[14]|abstract|abstract[17]	new[14]|new|new[17]	coref|coref|coref|coref	9-24|9-24[58_17]|9-24|9-24[58_17]
4-26	301-309	mitotane	abstract[14]|abstract|abstract[17]	new[14]|new|new[17]	coref	5-14[23_0]
4-27	310-317	therapy	abstract[14]|abstract[17]	new[14]|new[17]	_	_
4-28	318-327	following	_	_	_	_
4-29	328-336	surgical	event[18]	new[18]	_	_
4-30	337-346	operation	event[18]	new[18]	_	_
4-31	347-348	.	_	_	_	_

#Text=However , a limited number of often small-sized studies reporting the outcome of adjuvant mitotane is available .
5-1	349-356	However	_	_	_	_
5-2	357-358	,	_	_	_	_
5-3	359-360	a	quantity[19]	new[19]	_	_
5-4	361-368	limited	quantity[19]	new[19]	_	_
5-5	369-375	number	quantity[19]	new[19]	_	_
5-6	376-378	of	quantity[19]	new[19]	_	_
5-7	379-384	often	quantity[19]|event[20]	new[19]|new[20]	coref	7-1[34_20]
5-8	385-396	small-sized	quantity[19]|event[20]	new[19]|new[20]	_	_
5-9	397-404	studies	quantity[19]|event[20]	new[19]|new[20]	_	_
5-10	405-414	reporting	_	_	_	_
5-11	415-418	the	event[21]	new[21]	coref	6-15[30_21]
5-12	419-426	outcome	event[21]	new[21]	_	_
5-13	427-429	of	event[21]	new[21]	_	_
5-14	430-438	adjuvant	event[21]|person|abstract[23]	new[21]|new|giv[23]	coref|coref|coref|coref	6-12[0_23]|11-14|6-12[0_23]|11-14
5-15	439-447	mitotane	event[21]|abstract[23]	new[21]|giv[23]	_	_
5-16	448-450	is	_	_	_	_
5-17	451-460	available	_	_	_	_
5-18	461-462	.	_	_	_	_

#Text=In the present study , we explored the relationship between target mitotane concentrations and patient outcome using the TTR , analogous to warfarin treatment .
6-1	463-465	In	_	_	_	_
6-2	466-469	the	abstract[24]	giv[24]	coref	12-2[69_24]
6-3	470-477	present	abstract[24]	giv[24]	_	_
6-4	478-483	study	abstract[24]	giv[24]	_	_
6-5	484-485	,	_	_	_	_
6-6	486-488	we	person	acc	ana	12-6
6-7	489-497	explored	_	_	_	_
6-8	498-501	the	abstract[26]	new[26]	coref	13-3[82_26]
6-9	502-514	relationship	abstract[26]	new[26]	_	_
6-10	515-522	between	abstract[26]	new[26]	_	_
6-11	523-529	target	abstract[26]|animal[28]	new[26]|new[28]	coref	15-6[99_28]
6-12	530-538	mitotane	abstract[26]|abstract|animal[28]	new[26]|giv|new[28]	coref	7-7
6-13	539-553	concentrations	abstract[26]|animal[28]	new[26]|new[28]	_	_
6-14	554-557	and	abstract[26]	new[26]	_	_
6-15	558-565	patient	abstract[26]|person|event[30]	new[26]|new|giv[30]	_	_
6-16	566-573	outcome	abstract[26]|event[30]	new[26]|giv[30]	_	_
6-17	574-579	using	_	_	_	_
6-18	580-583	the	abstract[31]	new[31]	coref	12-8[71_31]
6-19	584-587	TTR	abstract[31]	new[31]	_	_
6-20	588-589	,	_	_	_	_
6-21	590-599	analogous	_	_	_	_
6-22	600-602	to	_	_	_	_
6-23	603-611	warfarin	person|event[33]	new|new[33]	coref|coref	11-14[68_33]|11-14[68_33]
6-24	612-621	treatment	event[33]	new[33]	_	_
6-25	622-623	.	_	_	_	_

#Text=Some previous studies used the peak mitotane level , which cannot give an adequate representation since it is a measurement at a single point in time .
7-1	624-628	Some	event[34]	giv[34]	coref	8-2[42_34]
7-2	629-637	previous	event[34]	giv[34]	_	_
7-3	638-645	studies	event[34]	giv[34]	_	_
7-4	646-650	used	_	_	_	_
7-5	651-654	the	quantity[37]	new[37]	coref	10-9[61_37]
7-6	655-659	peak	place|quantity[37]	new|new[37]	_	_
7-7	660-668	mitotane	abstract|quantity[37]	giv|new[37]	coref	8-8
7-8	669-674	level	quantity[37]	new[37]	_	_
7-9	675-676	,	_	_	_	_
7-10	677-682	which	_	_	_	_
7-11	683-689	cannot	_	_	_	_
7-12	690-694	give	_	_	_	_
7-13	695-697	an	abstract[38]	new[38]	ana	7-17[0_38]
7-14	698-706	adequate	abstract[38]	new[38]	_	_
7-15	707-721	representation	abstract[38]	new[38]	_	_
7-16	722-727	since	_	_	_	_
7-17	728-730	it	abstract	giv	coref	7-19[40_0]
7-18	731-733	is	_	_	_	_
7-19	734-735	a	abstract[40]	giv[40]	coref	12-16[74_40]
7-20	736-747	measurement	abstract[40]	giv[40]	_	_
7-21	748-750	at	abstract[40]	giv[40]	_	_
7-22	751-752	a	abstract[40]|time[41]	giv[40]|new[41]	coref	19-3[137_41]
7-23	753-759	single	abstract[40]|time[41]	giv[40]|new[41]	_	_
7-24	760-765	point	abstract[40]|time[41]	giv[40]|new[41]	_	_
7-25	766-768	in	abstract[40]|time[41]	giv[40]|new[41]	_	_
7-26	769-773	time	abstract[40]|time[41]	giv[40]|new[41]	_	_
7-27	774-775	.	_	_	_	_

#Text=In other studies , the percentage of mitotane measurements in a range was used , but this method has the caveat of being strongly dependent on the number of available measurements .
8-1	776-778	In	_	_	_	_
8-2	779-784	other	event[42]	giv[42]	_	_
8-3	785-792	studies	event[42]	giv[42]	_	_
8-4	793-794	,	_	_	_	_
8-5	795-798	the	abstract[43]	new[43]	coref	10-10[0_43]
8-6	799-809	percentage	abstract[43]	new[43]	_	_
8-7	810-812	of	abstract[43]	new[43]	_	_
8-8	813-821	mitotane	abstract[43]|abstract|abstract[45]	new[43]|giv|new[45]	coref|coref|coref|coref	8-30[50_45]|10-17|8-30[50_45]|10-17
8-9	822-834	measurements	abstract[43]|abstract[45]	new[43]|new[45]	_	_
8-10	835-837	in	abstract[43]|abstract[45]	new[43]|new[45]	_	_
8-11	838-839	a	abstract[43]|abstract[45]|abstract[46]	new[43]|new[45]|new[46]	coref	18-25[134_46]
8-12	840-845	range	abstract[43]|abstract[45]|abstract[46]	new[43]|new[45]|new[46]	_	_
8-13	846-849	was	_	_	_	_
8-14	850-854	used	_	_	_	_
8-15	855-856	,	_	_	_	_
8-16	857-860	but	_	_	_	_
8-17	861-865	this	abstract[47]	new[47]	_	_
8-18	866-872	method	abstract[47]	new[47]	_	_
8-19	873-876	has	_	_	_	_
8-20	877-880	the	abstract[48]	new[48]	ana	9-1[0_48]
8-21	881-887	caveat	abstract[48]	new[48]	_	_
8-22	888-890	of	_	_	_	_
8-23	891-896	being	_	_	_	_
8-24	897-905	strongly	_	_	_	_
8-25	906-915	dependent	_	_	_	_
8-26	916-918	on	_	_	_	_
8-27	919-922	the	quantity[49]	new[49]	_	_
8-28	923-929	number	quantity[49]	new[49]	_	_
8-29	930-932	of	quantity[49]	new[49]	_	_
8-30	933-942	available	quantity[49]|abstract[50]	new[49]|giv[50]	_	_
8-31	943-955	measurements	quantity[49]|abstract[50]	new[49]|giv[50]	_	_
8-32	956-957	.	_	_	_	_

#Text=This may introduce a bias when comparing patients with different durations of follow-ups , which may be quite prolonged in the case of adjuvant therapy .
9-1	958-962	This	abstract	giv	_	_
9-2	963-966	may	_	_	_	_
9-3	967-976	introduce	_	_	_	_
9-4	977-978	a	abstract[52]	new[52]	_	_
9-5	979-983	bias	abstract[52]	new[52]	_	_
9-6	984-988	when	_	_	_	_
9-7	989-998	comparing	_	_	_	_
9-8	999-1007	patients	person[53]	giv[53]	coref	19-17[0_53]
9-9	1008-1012	with	person[53]	giv[53]	_	_
9-10	1013-1022	different	person[53]|abstract[54]	giv[53]|new[54]	_	_
9-11	1023-1032	durations	person[53]|abstract[54]	giv[53]|new[54]	_	_
9-12	1033-1035	of	person[53]|abstract[54]	giv[53]|new[54]	_	_
9-13	1036-1046	follow-ups	person[53]|abstract[54]|event	giv[53]|new[54]|new	_	_
9-14	1047-1048	,	_	_	_	_
9-15	1049-1054	which	_	_	_	_
9-16	1055-1058	may	_	_	_	_
9-17	1059-1061	be	_	_	_	_
9-18	1062-1067	quite	_	_	_	_
9-19	1068-1077	prolonged	_	_	_	_
9-20	1078-1080	in	_	_	_	_
9-21	1081-1084	the	abstract[56]	new[56]	_	_
9-22	1085-1089	case	abstract[56]	new[56]	_	_
9-23	1090-1092	of	abstract[56]	new[56]	_	_
9-24	1093-1101	adjuvant	abstract[56]|abstract|abstract[58]	new[56]|giv|giv[58]	coref|coref	25-15[201_58]|25-15[201_58]
9-25	1102-1109	therapy	abstract[56]|abstract[58]	new[56]|giv[58]	_	_
9-26	1110-1111	.	_	_	_	_

#Text=Moreover , there is no evidence to define what percentage level identifies a good exposure to mitotane .
10-1	1112-1120	Moreover	_	_	_	_
10-2	1121-1122	,	_	_	_	_
10-3	1123-1128	there	_	_	_	_
10-4	1129-1131	is	_	_	_	_
10-5	1132-1134	no	abstract[59]	new[59]	_	_
10-6	1135-1143	evidence	abstract[59]	new[59]	_	_
10-7	1144-1146	to	_	_	_	_
10-8	1147-1153	define	_	_	_	_
10-9	1154-1158	what	quantity[61]	giv[61]	coref	15-19[104_61]
10-10	1159-1169	percentage	abstract|quantity[61]	giv|giv[61]	_	_
10-11	1170-1175	level	quantity[61]	giv[61]	_	_
10-12	1176-1186	identifies	_	_	_	_
10-13	1187-1188	a	abstract[62]	new[62]	coref	12-21[75_62]
10-14	1189-1193	good	abstract[62]	new[62]	_	_
10-15	1194-1202	exposure	abstract[62]	new[62]	_	_
10-16	1203-1205	to	abstract[62]	new[62]	_	_
10-17	1206-1214	mitotane	abstract[62]|abstract	new[62]|giv	coref	12-24
10-18	1215-1216	.	_	_	_	_

#Text=These methodological issues may have contributed to the discrepancy in the literature concerning adjuvant treatment .
11-1	1217-1222	These	abstract[64]	new[64]	_	_
11-2	1223-1237	methodological	abstract[64]	new[64]	_	_
11-3	1238-1244	issues	abstract[64]	new[64]	_	_
11-4	1245-1248	may	_	_	_	_
11-5	1249-1253	have	_	_	_	_
11-6	1254-1265	contributed	_	_	_	_
11-7	1266-1268	to	_	_	_	_
11-8	1269-1272	the	abstract[65]	new[65]	_	_
11-9	1273-1284	discrepancy	abstract[65]	new[65]	_	_
11-10	1285-1287	in	abstract[65]	new[65]	_	_
11-11	1288-1291	the	abstract[65]|abstract[66]	new[65]|new[66]	_	_
11-12	1292-1302	literature	abstract[65]|abstract[66]	new[65]|new[66]	_	_
11-13	1303-1313	concerning	_	_	_	_
11-14	1314-1322	adjuvant	person|event[68]	giv|giv[68]	coref|coref|coref|coref	14-18|15-13[102_68]|14-18|15-13[102_68]
11-15	1323-1332	treatment	event[68]	giv[68]	_	_
11-16	1333-1334	.	_	_	_	_

#Text=In the present study , we calculated the TTR , which in our opinion gives a more adequate representation of chronic exposure to mitotane , and analyzed the results in a multivariate analysis without predefining arbitrary cutoff values .
12-1	1335-1337	In	_	_	_	_
12-2	1338-1341	the	abstract[69]	giv[69]	coref	24-22[0_69]
12-3	1342-1349	present	abstract[69]	giv[69]	_	_
12-4	1350-1355	study	abstract[69]	giv[69]	_	_
12-5	1356-1357	,	_	_	_	_
12-6	1358-1360	we	person	giv	ana	12-13
12-7	1361-1371	calculated	_	_	_	_
12-8	1372-1375	the	abstract[71]	giv[71]	coref	13-7[83_71]
12-9	1376-1379	TTR	abstract[71]	giv[71]	_	_
12-10	1380-1381	,	_	_	_	_
12-11	1382-1387	which	_	_	_	_
12-12	1388-1390	in	_	_	_	_
12-13	1391-1394	our	person|abstract[73]	giv|new[73]	ana|ana	13-1|13-1
12-14	1395-1402	opinion	abstract[73]	new[73]	_	_
12-15	1403-1408	gives	_	_	_	_
12-16	1409-1410	a	abstract[74]	giv[74]	_	_
12-17	1411-1415	more	abstract[74]	giv[74]	_	_
12-18	1416-1424	adequate	abstract[74]	giv[74]	_	_
12-19	1425-1439	representation	abstract[74]	giv[74]	_	_
12-20	1440-1442	of	abstract[74]	giv[74]	_	_
12-21	1443-1450	chronic	abstract[74]|abstract[75]	giv[74]|giv[75]	_	_
12-22	1451-1459	exposure	abstract[74]|abstract[75]	giv[74]|giv[75]	_	_
12-23	1460-1462	to	abstract[74]|abstract[75]	giv[74]|giv[75]	_	_
12-24	1463-1471	mitotane	abstract[74]|abstract[75]|abstract	giv[74]|giv[75]|giv	coref	14-8
12-25	1472-1473	,	_	_	_	_
12-26	1474-1477	and	_	_	_	_
12-27	1478-1486	analyzed	_	_	_	_
12-28	1487-1490	the	abstract[77]	new[77]	coref	31-15[256_77]
12-29	1491-1498	results	abstract[77]	new[77]	_	_
12-30	1499-1501	in	abstract[77]	new[77]	_	_
12-31	1502-1503	a	abstract[77]|abstract[78]	new[77]|new[78]	coref	31-9[254_78]
12-32	1504-1516	multivariate	abstract[77]|abstract[78]	new[77]|new[78]	_	_
12-33	1517-1525	analysis	abstract[77]|abstract[78]	new[77]|new[78]	_	_
12-34	1526-1533	without	_	_	_	_
12-35	1534-1545	predefining	_	_	_	_
12-36	1546-1555	arbitrary	abstract[80]	new[80]	_	_
12-37	1556-1562	cutoff	abstract|abstract[80]	new|new[80]	_	_
12-38	1563-1569	values	abstract[80]	new[80]	_	_
12-39	1570-1571	.	_	_	_	_

#Text=We found an inverse relationship between the TTR and risk of ACC recurrence , implying that the greater the TTR , the lower the risk .
13-1	1572-1574	We	person	giv	ana	15-17
13-2	1575-1580	found	_	_	_	_
13-3	1581-1583	an	abstract[82]	giv[82]	coref	22-3[161_82]
13-4	1584-1591	inverse	abstract[82]	giv[82]	_	_
13-5	1592-1604	relationship	abstract[82]	giv[82]	_	_
13-6	1605-1612	between	abstract[82]	giv[82]	_	_
13-7	1613-1616	the	abstract[82]|abstract[83]	giv[82]|giv[83]	coref	13-19[87_83]
13-8	1617-1620	TTR	abstract[82]|abstract[83]	giv[82]|giv[83]	_	_
13-9	1621-1624	and	abstract[82]	giv[82]	_	_
13-10	1625-1629	risk	abstract[82]|abstract[84]	giv[82]|new[84]	coref	13-24[88_84]
13-11	1630-1632	of	abstract[82]|abstract[84]	giv[82]|new[84]	_	_
13-12	1633-1636	ACC	abstract[82]|abstract[84]|abstract|abstract[86]	giv[82]|new[84]|giv|giv[86]	coref|coref|coref|coref	16-17|16-17[116_86]|16-17|16-17[116_86]
13-13	1637-1647	recurrence	abstract[82]|abstract[84]|abstract[86]	giv[82]|new[84]|giv[86]	_	_
13-14	1648-1649	,	_	_	_	_
13-15	1650-1658	implying	_	_	_	_
13-16	1659-1663	that	_	_	_	_
13-17	1664-1667	the	_	_	_	_
13-18	1668-1675	greater	_	_	_	_
13-19	1676-1679	the	abstract[87]	giv[87]	_	_
13-20	1680-1683	TTR	abstract[87]	giv[87]	_	_
13-21	1684-1685	,	_	_	_	_
13-22	1686-1689	the	_	_	_	_
13-23	1690-1695	lower	_	_	_	_
13-24	1696-1699	the	abstract[88]	giv[88]	_	_
13-25	1700-1704	risk	abstract[88]	giv[88]	_	_
13-26	1705-1706	.	_	_	_	_

#Text=This finding supports the clinical value of mitotane monitoring and the concept of target doses in the adjuvant setting .
14-1	1707-1711	This	abstract[89]	new[89]	coref	22-22[168_89]
14-2	1712-1719	finding	abstract[89]	new[89]	_	_
14-3	1720-1728	supports	_	_	_	_
14-4	1729-1732	the	abstract[90]	new[90]	_	_
14-5	1733-1741	clinical	abstract[90]	new[90]	_	_
14-6	1742-1747	value	abstract[90]	new[90]	_	_
14-7	1748-1750	of	abstract[90]	new[90]	_	_
14-8	1751-1759	mitotane	abstract[90]|abstract|abstract[92]	new[90]|giv|new[92]	coref|coref|coref|coref	15-7|20-24[151_92]|15-7|20-24[151_92]
14-9	1760-1770	monitoring	abstract[90]|abstract[92]	new[90]|new[92]	_	_
14-10	1771-1774	and	_	_	_	_
14-11	1775-1778	the	abstract[93]	new[93]	coref	17-5[120_93]
14-12	1779-1786	concept	abstract[93]	new[93]	_	_
14-13	1787-1789	of	abstract[93]	new[93]	_	_
14-14	1790-1796	target	abstract[93]|quantity[94]	new[93]|new[94]	coref	23-3[177_94]
14-15	1797-1802	doses	abstract[93]|quantity[94]	new[93]|new[94]	_	_
14-16	1803-1805	in	abstract[93]|quantity[94]	new[93]|new[94]	_	_
14-17	1806-1809	the	abstract[93]|quantity[94]|abstract[96]	new[93]|new[94]|new[96]	_	_
14-18	1810-1818	adjuvant	abstract[93]|quantity[94]|person|abstract[96]	new[93]|new[94]|giv|new[96]	coref	15-14
14-19	1819-1826	setting	abstract[93]|quantity[94]|abstract[96]	new[93]|new[94]|new[96]	_	_
14-20	1827-1828	.	_	_	_	_

#Text=Although it is plausible that lower mitotane concentrations may be effective in an adjuvant treatment , we analyzed only the level of 14 mg/L , because this was the target in our practice .
15-1	1829-1837	Although	_	_	_	_
15-2	1838-1840	it	abstract	new	cata	15-2[0_100]
15-3	1841-1843	is	_	_	_	_
15-4	1844-1853	plausible	_	_	_	_
15-5	1854-1858	that	abstract[100]	new[100]	ana	15-27[0_100]
15-6	1859-1864	lower	animal[99]|abstract[100]	giv[99]|new[100]	coref	16-6[112_99]
15-7	1865-1873	mitotane	abstract|animal[99]|abstract[100]	giv|giv[99]|new[100]	coref	16-7
15-8	1874-1888	concentrations	animal[99]|abstract[100]	giv[99]|new[100]	_	_
15-9	1889-1892	may	abstract[100]	new[100]	_	_
15-10	1893-1895	be	abstract[100]	new[100]	_	_
15-11	1896-1905	effective	abstract[100]	new[100]	_	_
15-12	1906-1908	in	_	_	_	_
15-13	1909-1911	an	event[102]	giv[102]	coref	18-13[0_102]
15-14	1912-1920	adjuvant	person|event[102]	giv|giv[102]	coref	24-8
15-15	1921-1930	treatment	event[102]	giv[102]	_	_
15-16	1931-1932	,	_	_	_	_
15-17	1933-1935	we	person	giv	ana	15-32
15-18	1936-1944	analyzed	_	_	_	_
15-19	1945-1949	only	quantity[104]	giv[104]	_	_
15-20	1950-1953	the	quantity[104]	giv[104]	_	_
15-21	1954-1959	level	quantity[104]	giv[104]	_	_
15-22	1960-1962	of	quantity[104]	giv[104]	_	_
15-23	1963-1965	14	quantity[104]|quantity[105]	giv[104]|new[105]	_	_
15-24	1966-1970	mg/L	quantity[104]|quantity[105]	giv[104]|new[105]	_	_
15-25	1971-1972	,	_	_	_	_
15-26	1973-1980	because	_	_	_	_
15-27	1981-1985	this	abstract	giv	coref	15-29[107_0]
15-28	1986-1989	was	_	_	_	_
15-29	1990-1993	the	abstract[107]	giv[107]	coref	18-26[0_107]
15-30	1994-2000	target	abstract[107]	giv[107]	_	_
15-31	2001-2003	in	abstract[107]	giv[107]	_	_
15-32	2004-2007	our	abstract[107]|person|abstract[109]	giv[107]|giv|new[109]	ana|coref|ana|coref	19-1|23-21[182_109]|19-1|23-21[182_109]
15-33	2008-2016	practice	abstract[107]|abstract[109]	giv[107]|new[109]	_	_
15-34	2017-2018	.	_	_	_	_

#Text=The time needed to achieve target mitotane concentrations also has an impact on the risk of ACC recurrence : a longer time was associated with higher risk .
16-1	2019-2022	The	time[110]	new[110]	_	_
16-2	2023-2027	time	time[110]	new[110]	_	_
16-3	2028-2034	needed	_	_	_	_
16-4	2035-2037	to	_	_	_	_
16-5	2038-2045	achieve	event	new	coref|none	17-16[124_0]|16-5[0_124]
16-6	2046-2052	target	animal[112]	giv[112]	coref	19-11[139_112]
16-7	2053-2061	mitotane	abstract|animal[112]	giv|giv[112]	coref	17-8
16-8	2062-2076	concentrations	animal[112]	giv[112]	_	_
16-9	2077-2081	also	_	_	_	_
16-10	2082-2085	has	_	_	_	_
16-11	2086-2088	an	abstract[113]	giv[113]	_	_
16-12	2089-2095	impact	abstract[113]	giv[113]	_	_
16-13	2096-2098	on	abstract[113]	giv[113]	_	_
16-14	2099-2102	the	abstract[113]|abstract[114]	giv[113]|new[114]	coref	16-26[118_114]
16-15	2103-2107	risk	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
16-16	2108-2110	of	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
16-17	2111-2114	ACC	abstract[113]|abstract[114]|abstract|event[116]	giv[113]|new[114]|giv|giv[116]	coref|coref|coref|coref	19-22[0_116]|29-15|19-22[0_116]|29-15
16-18	2115-2125	recurrence	abstract[113]|abstract[114]|event[116]	giv[113]|new[114]|giv[116]	_	_
16-19	2126-2127	:	_	_	_	_
16-20	2128-2129	a	time[117]	new[117]	coref	18-19[132_117]
16-21	2130-2136	longer	time[117]	new[117]	_	_
16-22	2137-2141	time	time[117]	new[117]	_	_
16-23	2142-2145	was	_	_	_	_
16-24	2146-2156	associated	_	_	_	_
16-25	2157-2161	with	_	_	_	_
16-26	2162-2168	higher	abstract[118]	giv[118]	ana	17-1[0_118]
16-27	2169-2173	risk	abstract[118]	giv[118]	_	_
16-28	2174-2175	.	_	_	_	_

#Text=This is consistent with the concept that mitotane is a slow-acting drug in relation to the achievement of significant plasma levels .
17-1	2176-2180	This	abstract	giv	_	_
17-2	2181-2183	is	_	_	_	_
17-3	2184-2194	consistent	_	_	_	_
17-4	2195-2199	with	_	_	_	_
17-5	2200-2203	the	abstract[120]	giv[120]	coref	22-28[170_120]
17-6	2204-2211	concept	abstract[120]	giv[120]	_	_
17-7	2212-2216	that	abstract[120]	giv[120]	_	_
17-8	2217-2225	mitotane	abstract[120]|substance	giv[120]|giv	coref	17-10[122_0]
17-9	2226-2228	is	abstract[120]	giv[120]	_	_
17-10	2229-2230	a	abstract[120]|substance[122]	giv[120]|giv[122]	coref	20-17[0_122]
17-11	2231-2242	slow-acting	abstract[120]|substance[122]	giv[120]|giv[122]	_	_
17-12	2243-2247	drug	abstract[120]|substance[122]	giv[120]|giv[122]	_	_
17-13	2248-2250	in	abstract[120]|substance[122]	giv[120]|giv[122]	_	_
17-14	2251-2259	relation	abstract[120]|substance[122]|abstract[123]	giv[120]|giv[122]|new[123]	_	_
17-15	2260-2262	to	abstract[120]|substance[122]|abstract[123]	giv[120]|giv[122]|new[123]	_	_
17-16	2263-2266	the	abstract[120]|substance[122]|abstract[123]|event[124]	giv[120]|giv[122]|new[123]|new[124]	_	_
17-17	2267-2278	achievement	abstract[120]|substance[122]|abstract[123]|event[124]	giv[120]|giv[122]|new[123]|new[124]	_	_
17-18	2279-2281	of	abstract[120]|substance[122]|abstract[123]|event[124]	giv[120]|giv[122]|new[123]|new[124]	_	_
17-19	2282-2293	significant	abstract[120]|substance[122]|abstract[123]|event[124]|abstract[126]	giv[120]|giv[122]|new[123]|new[124]|new[126]	coref	20-17[148_126]
17-20	2294-2300	plasma	abstract[120]|substance[122]|abstract[123]|event[124]|abstract|abstract[126]	giv[120]|giv[122]|new[123]|new[124]|new|new[126]	coref	22-12
17-21	2301-2307	levels	abstract[120]|substance[122]|abstract[123]|event[124]|abstract[126]	giv[120]|giv[122]|new[123]|new[124]|new[126]	_	_
17-22	2308-2309	.	_	_	_	_

#Text=Due to the very cautious dose titration in the starting phase of treatment employed in many centers , the time needed to get into the target range was exceedingly long .
18-1	2310-2313	Due	_	_	_	_
18-2	2314-2316	to	_	_	_	_
18-3	2317-2320	the	abstract[128]	new[128]	_	_
18-4	2321-2325	very	abstract[128]	new[128]	_	_
18-5	2326-2334	cautious	abstract[128]	new[128]	_	_
18-6	2335-2339	dose	quantity|abstract[128]	new|new[128]	coref	22-8[163_0]
18-7	2340-2349	titration	abstract[128]	new[128]	_	_
18-8	2350-2352	in	abstract[128]	new[128]	_	_
18-9	2353-2356	the	abstract[128]|abstract[129]	new[128]|new[129]	_	_
18-10	2357-2365	starting	abstract[128]|abstract[129]	new[128]|new[129]	_	_
18-11	2366-2371	phase	abstract[128]|abstract[129]	new[128]|new[129]	_	_
18-12	2372-2374	of	abstract[128]|abstract[129]	new[128]|new[129]	_	_
18-13	2375-2384	treatment	abstract[128]|abstract[129]|event	new[128]|new[129]|giv	coref	21-26
18-14	2385-2393	employed	_	_	_	_
18-15	2394-2396	in	_	_	_	_
18-16	2397-2401	many	place[131]	new[131]	coref	27-24[223_131]
18-17	2402-2409	centers	place[131]	new[131]	_	_
18-18	2410-2411	,	_	_	_	_
18-19	2412-2415	the	time[132]	giv[132]	coref	19-4[0_132]
18-20	2416-2420	time	time[132]	giv[132]	_	_
18-21	2421-2427	needed	_	_	_	_
18-22	2428-2430	to	_	_	_	_
18-23	2431-2434	get	_	_	_	_
18-24	2435-2439	into	_	_	_	_
18-25	2440-2443	the	abstract[134]	giv[134]	_	_
18-26	2444-2450	target	abstract|abstract[134]	giv|giv[134]	_	_
18-27	2451-2456	range	abstract[134]	giv[134]	_	_
18-28	2457-2460	was	_	_	_	_
18-29	2461-2472	exceedingly	_	_	_	_
18-30	2473-2477	long	_	_	_	_
18-31	2478-2479	.	_	_	_	_

#Text=We identified a time point at 17 months to achieve target concentrations , which significantly differentiates patients for their risk of recurrence .
19-1	2480-2482	We	person	giv	ana	22-1
19-2	2483-2493	identified	_	_	_	_
19-3	2494-2495	a	time[137]	giv[137]	_	_
19-4	2496-2500	time	time|time[137]	giv|giv[137]	_	_
19-5	2501-2506	point	time[137]	giv[137]	_	_
19-6	2507-2509	at	_	_	_	_
19-7	2510-2512	17	time[138]	new[138]	_	_
19-8	2513-2519	months	time[138]	new[138]	_	_
19-9	2520-2522	to	_	_	_	_
19-10	2523-2530	achieve	_	_	_	_
19-11	2531-2537	target	animal[139]	giv[139]	coref	22-11[165_139]
19-12	2538-2552	concentrations	animal[139]	giv[139]	_	_
19-13	2553-2554	,	_	_	_	_
19-14	2555-2560	which	_	_	_	_
19-15	2561-2574	significantly	_	_	_	_
19-16	2575-2589	differentiates	_	_	_	_
19-17	2590-2598	patients	person	giv	ana	19-19
19-18	2599-2602	for	_	_	_	_
19-19	2603-2608	their	person|abstract[142]	giv|new[142]	coref|coref	23-11[179_0]|23-11[179_0]
19-20	2609-2613	risk	abstract[142]	new[142]	_	_
19-21	2614-2616	of	abstract[142]	new[142]	_	_
19-22	2617-2627	recurrence	abstract[142]|abstract	new[142]|giv	coref	31-33[263_0]
19-23	2628-2629	.	_	_	_	_

#Text=The present findings call for a change in practice , aiming for a faster rise in mitotane levels and strengthening the value of mitotane monitoring .
20-1	2630-2633	The	abstract[144]	new[144]	coref	23-16[181_144]
20-2	2634-2641	present	abstract[144]	new[144]	_	_
20-3	2642-2650	findings	abstract[144]	new[144]	_	_
20-4	2651-2655	call	_	_	_	_
20-5	2656-2659	for	_	_	_	_
20-6	2660-2661	a	abstract[145]	new[145]	_	_
20-7	2662-2668	change	abstract[145]	new[145]	_	_
20-8	2669-2671	in	abstract[145]	new[145]	_	_
20-9	2672-2680	practice	abstract[145]	new[145]	_	_
20-10	2681-2682	,	_	_	_	_
20-11	2683-2689	aiming	_	_	_	_
20-12	2690-2693	for	_	_	_	_
20-13	2694-2695	a	abstract[146]	new[146]	_	_
20-14	2696-2702	faster	abstract[146]	new[146]	_	_
20-15	2703-2707	rise	abstract[146]	new[146]	_	_
20-16	2708-2710	in	abstract[146]	new[146]	_	_
20-17	2711-2719	mitotane	abstract[146]|abstract|abstract[148]	new[146]|giv|giv[148]	coref|coref	20-24|20-24
20-18	2720-2726	levels	abstract[146]|abstract[148]	new[146]|giv[148]	_	_
20-19	2727-2730	and	_	_	_	_
20-20	2731-2744	strengthening	_	_	_	_
20-21	2745-2748	the	abstract[149]	new[149]	_	_
20-22	2749-2754	value	abstract[149]	new[149]	_	_
20-23	2755-2757	of	abstract[149]	new[149]	_	_
20-24	2758-2766	mitotane	abstract[149]|abstract|abstract[151]	new[149]|giv|giv[151]	coref|coref	21-11|21-11
20-25	2767-2777	monitoring	abstract[149]|abstract[151]	new[149]|giv[151]	_	_
20-26	2778-2779	.	_	_	_	_

#Text=However , the potential danger of a rapid increment in mitotane dosing , which may result in important toxicity with consequent loss of compliance to treatment , should be considered .
21-1	2780-2787	However	_	_	_	_
21-2	2788-2789	,	_	_	_	_
21-3	2790-2793	the	quantity[152]	new[152]	_	_
21-4	2794-2803	potential	quantity[152]	new[152]	_	_
21-5	2804-2810	danger	quantity[152]	new[152]	_	_
21-6	2811-2813	of	quantity[152]	new[152]	_	_
21-7	2814-2815	a	quantity[152]|event[153]	new[152]|new[153]	_	_
21-8	2816-2821	rapid	quantity[152]|event[153]	new[152]|new[153]	_	_
21-9	2822-2831	increment	quantity[152]|event[153]	new[152]|new[153]	_	_
21-10	2832-2834	in	quantity[152]|event[153]	new[152]|new[153]	_	_
21-11	2835-2843	mitotane	quantity[152]|event[153]|abstract|quantity[155]	new[152]|new[153]|giv|new[155]	coref|coref	22-8|22-8
21-12	2844-2850	dosing	quantity[152]|event[153]|quantity[155]	new[152]|new[153]|new[155]	_	_
21-13	2851-2852	,	_	_	_	_
21-14	2853-2858	which	_	_	_	_
21-15	2859-2862	may	_	_	_	_
21-16	2863-2869	result	_	_	_	_
21-17	2870-2872	in	_	_	_	_
21-18	2873-2882	important	abstract[156]	new[156]	coref	24-5[0_156]
21-19	2883-2891	toxicity	abstract[156]	new[156]	_	_
21-20	2892-2896	with	_	_	_	_
21-21	2897-2907	consequent	abstract[157]	new[157]	_	_
21-22	2908-2912	loss	abstract[157]	new[157]	_	_
21-23	2913-2915	of	abstract[157]	new[157]	_	_
21-24	2916-2926	compliance	abstract[157]|abstract[158]	new[157]|new[158]	_	_
21-25	2927-2929	to	abstract[157]|abstract[158]	new[157]|new[158]	_	_
21-26	2930-2939	treatment	abstract[157]|abstract[158]|event	new[157]|new[158]|giv	coref	22-19
21-27	2940-2941	,	_	_	_	_
21-28	2942-2948	should	_	_	_	_
21-29	2949-2951	be	_	_	_	_
21-30	2952-2962	considered	_	_	_	_
21-31	2963-2964	.	_	_	_	_

#Text=We found only a weak relationship between mitotane dose and its plasma concentrations during the first phase of treatment , and this finding is in agreement with the concept that individual differences in mitotane metabolism and other still unknown factors influence plasma concentrations .
22-1	2965-2967	We	person	giv	ana	24-2
22-2	2968-2973	found	_	_	_	_
22-3	2974-2978	only	abstract[161]	giv[161]	_	_
22-4	2979-2980	a	abstract[161]	giv[161]	_	_
22-5	2981-2985	weak	abstract[161]	giv[161]	_	_
22-6	2986-2998	relationship	abstract[161]	giv[161]	_	_
22-7	2999-3006	between	abstract[161]	giv[161]	_	_
22-8	3007-3015	mitotane	abstract[161]|abstract|quantity[163]	giv[161]|giv|giv[163]	coref|coref|coref|coref	22-34|25-28[204_163]|22-34|25-28[204_163]
22-9	3016-3020	dose	abstract[161]|quantity[163]	giv[161]|giv[163]	_	_
22-10	3021-3024	and	abstract[161]	giv[161]	_	_
22-11	3025-3028	its	abstract[161]|animal[165]	giv[161]|giv[165]	coref	22-42[176_165]
22-12	3029-3035	plasma	abstract[161]|substance|animal[165]	giv[161]|giv|giv[165]	coref	22-42
22-13	3036-3050	concentrations	abstract[161]|animal[165]	giv[161]|giv[165]	_	_
22-14	3051-3057	during	_	_	_	_
22-15	3058-3061	the	abstract[166]	new[166]	coref	25-39[208_166]
22-16	3062-3067	first	abstract[166]	new[166]	_	_
22-17	3068-3073	phase	abstract[166]	new[166]	_	_
22-18	3074-3076	of	abstract[166]	new[166]	_	_
22-19	3077-3086	treatment	abstract[166]|event	new[166]|giv	coref	25-6
22-20	3087-3088	,	_	_	_	_
22-21	3089-3092	and	_	_	_	_
22-22	3093-3097	this	abstract[168]	giv[168]	_	_
22-23	3098-3105	finding	abstract[168]	giv[168]	_	_
22-24	3106-3108	is	_	_	_	_
22-25	3109-3111	in	_	_	_	_
22-26	3112-3121	agreement	abstract[169]	new[169]	_	_
22-27	3122-3126	with	abstract[169]	new[169]	_	_
22-28	3127-3130	the	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
22-29	3131-3138	concept	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
22-30	3139-3143	that	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
22-31	3144-3154	individual	abstract[169]|abstract[170]|abstract[171]	new[169]|giv[170]|new[171]	_	_
22-32	3155-3166	differences	abstract[169]|abstract[170]|abstract[171]	new[169]|giv[170]|new[171]	_	_
22-33	3167-3169	in	abstract[169]|abstract[170]|abstract[171]	new[169]|giv[170]|new[171]	_	_
22-34	3170-3178	mitotane	abstract[169]|abstract[170]|abstract[171]|abstract|abstract[173]	new[169]|giv[170]|new[171]|giv|new[173]	coref|coref|coref|coref	24-8[187_0]|28-32[231_173]|24-8[187_0]|28-32[231_173]
22-35	3179-3189	metabolism	abstract[169]|abstract[170]|abstract[171]|abstract[173]	new[169]|giv[170]|new[171]|new[173]	_	_
22-36	3190-3193	and	abstract[169]|abstract[170]|abstract[171]	new[169]|giv[170]|new[171]	_	_
22-37	3194-3199	other	abstract[169]|abstract[170]|abstract[171]|abstract[174]	new[169]|giv[170]|new[171]|new[174]	coref	28-29[229_174]
22-38	3200-3205	still	abstract[169]|abstract[170]|abstract[171]|abstract[174]	new[169]|giv[170]|new[171]|new[174]	_	_
22-39	3206-3213	unknown	abstract[169]|abstract[170]|abstract[171]|abstract[174]	new[169]|giv[170]|new[171]|new[174]	_	_
22-40	3214-3221	factors	abstract[169]|abstract[170]|abstract[171]|abstract[174]	new[169]|giv[170]|new[171]|new[174]	_	_
22-41	3222-3231	influence	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
22-42	3232-3238	plasma	abstract[169]|abstract[170]|substance|animal[176]	new[169]|giv[170]|giv|giv[176]	coref|coref	28-19[227_176]|28-19[227_176]
22-43	3239-3253	concentrations	abstract[169]|abstract[170]|animal[176]	new[169]|giv[170]|giv[176]	_	_
22-44	3254-3255	.	_	_	_	_

#Text=Interestingly , higher doses were employed in men and in patients with greater BMI and these novel findings matter for clinical practice .
23-1	3256-3269	Interestingly	_	_	_	_
23-2	3270-3271	,	_	_	_	_
23-3	3272-3278	higher	quantity[177]	giv[177]	coref	25-24[203_177]
23-4	3279-3284	doses	quantity[177]	giv[177]	_	_
23-5	3285-3289	were	_	_	_	_
23-6	3290-3298	employed	_	_	_	_
23-7	3299-3301	in	_	_	_	_
23-8	3302-3305	men	person	new	_	_
23-9	3306-3309	and	_	_	_	_
23-10	3310-3312	in	_	_	_	_
23-11	3313-3321	patients	person[179]	giv[179]	coref	24-29[194_179]
23-12	3322-3326	with	person[179]	giv[179]	_	_
23-13	3327-3334	greater	person[179]|abstract[180]	giv[179]|new[180]	_	_
23-14	3335-3338	BMI	person[179]|abstract[180]	giv[179]|new[180]	_	_
23-15	3339-3342	and	_	_	_	_
23-16	3343-3348	these	abstract[181]	giv[181]	_	_
23-17	3349-3354	novel	abstract[181]	giv[181]	_	_
23-18	3355-3363	findings	abstract[181]	giv[181]	_	_
23-19	3364-3370	matter	_	_	_	_
23-20	3371-3374	for	_	_	_	_
23-21	3375-3383	clinical	abstract[182]	giv[182]	coref	30-28[251_182]
23-22	3384-3392	practice	abstract[182]	giv[182]	_	_
23-23	3393-3394	.	_	_	_	_

#Text=In our cohort , toxicity associated with adjuvant mitotane was acceptable , though we acknowledge the fact that due to the study inclusion criteria we did not capture the patients who eventually discontinued mitotane in the first six months .
24-1	3395-3397	In	_	_	_	_
24-2	3398-3401	our	person|person[184]	giv|new[184]	ana|ana	24-14|24-14
24-3	3402-3408	cohort	person[184]	new[184]	_	_
24-4	3409-3410	,	_	_	_	_
24-5	3411-3419	toxicity	abstract	giv	coref	25-1[197_0]
24-6	3420-3430	associated	_	_	_	_
24-7	3431-3435	with	_	_	_	_
24-8	3436-3444	adjuvant	person|abstract[187]	giv|giv[187]	coref|coref|coref|coref	24-34[0_187]|26-13|24-34[0_187]|26-13
24-9	3445-3453	mitotane	abstract[187]	giv[187]	_	_
24-10	3454-3457	was	_	_	_	_
24-11	3458-3468	acceptable	_	_	_	_
24-12	3469-3470	,	_	_	_	_
24-13	3471-3477	though	_	_	_	_
24-14	3478-3480	we	person	giv	ana	24-25
24-15	3481-3492	acknowledge	_	_	_	_
24-16	3493-3496	the	abstract[189]	new[189]	_	_
24-17	3497-3501	fact	abstract[189]	new[189]	_	_
24-18	3502-3506	that	abstract[189]	new[189]	_	_
24-19	3507-3510	due	abstract[189]	new[189]	_	_
24-20	3511-3513	to	_	_	_	_
24-21	3514-3517	the	abstract[192]	new[192]	coref	32-1[265_192]
24-22	3518-3523	study	abstract|abstract[192]	giv|new[192]	coref	26-3[209_0]
24-23	3524-3533	inclusion	person|abstract[192]	new|new[192]	coref	32-2
24-24	3534-3542	criteria	abstract[192]	new[192]	_	_
24-25	3543-3545	we	person	giv	ana	31-3
24-26	3546-3549	did	_	_	_	_
24-27	3550-3553	not	_	_	_	_
24-28	3554-3561	capture	abstract	new	coref|none	30-4[246_0]|24-28[0_246]
24-29	3562-3565	the	person[194]	giv[194]	coref	25-11[200_194]
24-30	3566-3574	patients	person[194]	giv[194]	_	_
24-31	3575-3578	who	_	_	_	_
24-32	3579-3589	eventually	_	_	_	_
24-33	3590-3602	discontinued	_	_	_	_
24-34	3603-3611	mitotane	abstract	giv	coref	26-13[212_0]
24-35	3612-3614	in	_	_	_	_
24-36	3615-3618	the	time[196]	new[196]	coref	31-26[259_196]
24-37	3619-3624	first	time[196]	new[196]	_	_
24-38	3625-3628	six	time[196]	new[196]	_	_
24-39	3629-3635	months	time[196]	new[196]	_	_
24-40	3636-3637	.	_	_	_	_

#Text=Severe toxicity leading to permanent treatment discontinuation was recorded in only five patients on chronic therapy , and this is likely due to the low doses ( median dose of 2 g/day ) used to continue treatment in the maintenance phase .
25-1	3638-3644	Severe	abstract[197]	giv[197]	coref	28-13[226_197]
25-2	3645-3653	toxicity	abstract[197]	giv[197]	_	_
25-3	3654-3661	leading	_	_	_	_
25-4	3662-3664	to	_	_	_	_
25-5	3665-3674	permanent	event[199]	new[199]	_	_
25-6	3675-3684	treatment	event|event[199]	giv|new[199]	coref	25-37
25-7	3685-3700	discontinuation	event[199]	new[199]	_	_
25-8	3701-3704	was	_	_	_	_
25-9	3705-3713	recorded	_	_	_	_
25-10	3714-3716	in	_	_	_	_
25-11	3717-3721	only	person[200]	giv[200]	coref	26-8[210_200]
25-12	3722-3726	five	person[200]	giv[200]	_	_
25-13	3727-3735	patients	person[200]	giv[200]	_	_
25-14	3736-3738	on	person[200]	giv[200]	_	_
25-15	3739-3746	chronic	person[200]|abstract[201]	giv[200]|giv[201]	ana	25-19[0_201]
25-16	3747-3754	therapy	person[200]|abstract[201]	giv[200]|giv[201]	_	_
25-17	3755-3756	,	_	_	_	_
25-18	3757-3760	and	_	_	_	_
25-19	3761-3765	this	abstract	giv	_	_
25-20	3766-3768	is	_	_	_	_
25-21	3769-3775	likely	_	_	_	_
25-22	3776-3779	due	_	_	_	_
25-23	3780-3782	to	_	_	_	_
25-24	3783-3786	the	quantity[203]	giv[203]	_	_
25-25	3787-3790	low	quantity[203]	giv[203]	_	_
25-26	3791-3796	doses	quantity[203]	giv[203]	_	_
25-27	3797-3798	(	_	_	_	_
25-28	3799-3805	median	quantity[204]	giv[204]	_	_
25-29	3806-3810	dose	quantity[204]	giv[204]	_	_
25-30	3811-3813	of	quantity[204]	giv[204]	_	_
25-31	3814-3815	2	quantity[204]|quantity[205]	giv[204]|new[205]	_	_
25-32	3816-3821	g/day	quantity[204]|quantity[205]	giv[204]|new[205]	_	_
25-33	3822-3823	)	_	_	_	_
25-34	3824-3828	used	_	_	_	_
25-35	3829-3831	to	_	_	_	_
25-36	3832-3840	continue	_	_	_	_
25-37	3841-3850	treatment	event	giv	coref	26-20
25-38	3851-3853	in	_	_	_	_
25-39	3854-3857	the	abstract[208]	giv[208]	_	_
25-40	3858-3869	maintenance	abstract|abstract[208]	new|giv[208]	_	_
25-41	3870-3875	phase	abstract[208]	giv[208]	_	_
25-42	3876-3877	.	_	_	_	_

#Text=Thus , the present study shows that a few patients cannot tolerate adjuvant mitotane following the first months of treatment , proving than a careful follow-up is necessary .
26-1	3878-3882	Thus	_	_	_	_
26-2	3883-3884	,	_	_	_	_
26-3	3885-3888	the	abstract[209]	giv[209]	coref	29-3[233_209]
26-4	3889-3896	present	abstract[209]	giv[209]	_	_
26-5	3897-3902	study	abstract[209]	giv[209]	_	_
26-6	3903-3908	shows	_	_	_	_
26-7	3909-3913	that	_	_	_	_
26-8	3914-3915	a	person[210]	giv[210]	coref	27-20[0_210]
26-9	3916-3919	few	person[210]	giv[210]	_	_
26-10	3920-3928	patients	person[210]	giv[210]	_	_
26-11	3929-3935	cannot	_	_	_	_
26-12	3936-3944	tolerate	_	_	_	_
26-13	3945-3953	adjuvant	person|abstract[212]	giv|giv[212]	coref|coref|coref|coref	27-2[0_212]|29-11|27-2[0_212]|29-11
26-14	3954-3962	mitotane	abstract[212]	giv[212]	_	_
26-15	3963-3972	following	_	_	_	_
26-16	3973-3976	the	time[213]	new[213]	_	_
26-17	3977-3982	first	time[213]	new[213]	_	_
26-18	3983-3989	months	time[213]	new[213]	_	_
26-19	3990-3992	of	time[213]	new[213]	_	_
26-20	3993-4002	treatment	time[213]|event	new[213]|giv	coref	27-14[220_0]
26-21	4003-4004	,	_	_	_	_
26-22	4005-4012	proving	_	_	_	_
26-23	4013-4017	than	_	_	_	_
26-24	4018-4019	a	event[215]	new[215]	_	_
26-25	4020-4027	careful	event[215]	new[215]	_	_
26-26	4028-4037	follow-up	event[215]	new[215]	_	_
26-27	4038-4040	is	_	_	_	_
26-28	4041-4050	necessary	_	_	_	_
26-29	4051-4052	.	_	_	_	_

#Text=Despite mitotane having a reputation for being a challenging drug to manage , adjuvant mitotane treatment is feasible when patients are managed in expert centers .
27-1	4053-4060	Despite	_	_	_	_
27-2	4061-4069	mitotane	abstract	giv	coref	27-8[218_0]
27-3	4070-4076	having	_	_	_	_
27-4	4077-4078	a	abstract[217]	new[217]	_	_
27-5	4079-4089	reputation	abstract[217]	new[217]	_	_
27-6	4090-4093	for	abstract[217]	new[217]	_	_
27-7	4094-4099	being	abstract[217]	new[217]	_	_
27-8	4100-4101	a	abstract[217]|substance[218]	new[217]|giv[218]	coref	27-15[0_218]
27-9	4102-4113	challenging	abstract[217]|substance[218]	new[217]|giv[218]	_	_
27-10	4114-4118	drug	abstract[217]|substance[218]	new[217]|giv[218]	_	_
27-11	4119-4121	to	_	_	_	_
27-12	4122-4128	manage	_	_	_	_
27-13	4129-4130	,	_	_	_	_
27-14	4131-4139	adjuvant	event[220]	giv[220]	coref	29-11[237_220]
27-15	4140-4148	mitotane	abstract|event[220]	giv|giv[220]	coref	28-9[225_0]
27-16	4149-4158	treatment	event[220]	giv[220]	_	_
27-17	4159-4161	is	_	_	_	_
27-18	4162-4170	feasible	_	_	_	_
27-19	4171-4175	when	_	_	_	_
27-20	4176-4184	patients	person	giv	coref	28-3[224_0]
27-21	4185-4188	are	_	_	_	_
27-22	4189-4196	managed	_	_	_	_
27-23	4197-4199	in	_	_	_	_
27-24	4200-4206	expert	person|place[223]	new|giv[223]	_	_
27-25	4207-4214	centers	place[223]	giv[223]	_	_
27-26	4215-4216	.	_	_	_	_

#Text=However , some patients were unable to tolerate the drug , exhibiting neurological toxicity even when exposed to “ normal ” mitotane concentrations , confirming the relevance of individual factors in mitotane metabolism .
28-1	4217-4224	However	_	_	_	_
28-2	4225-4226	,	_	_	_	_
28-3	4227-4231	some	person[224]	giv[224]	coref	29-15[239_224]
28-4	4232-4240	patients	person[224]	giv[224]	_	_
28-5	4241-4245	were	_	_	_	_
28-6	4246-4252	unable	_	_	_	_
28-7	4253-4255	to	_	_	_	_
28-8	4256-4264	tolerate	_	_	_	_
28-9	4265-4268	the	substance[225]	giv[225]	coref	28-32[0_225]
28-10	4269-4273	drug	substance[225]	giv[225]	_	_
28-11	4274-4275	,	_	_	_	_
28-12	4276-4286	exhibiting	_	_	_	_
28-13	4287-4299	neurological	abstract[226]	giv[226]	_	_
28-14	4300-4308	toxicity	abstract[226]	giv[226]	_	_
28-15	4309-4313	even	_	_	_	_
28-16	4314-4318	when	_	_	_	_
28-17	4319-4326	exposed	_	_	_	_
28-18	4327-4329	to	_	_	_	_
28-19	4330-4331	“	animal[227]	giv[227]	_	_
28-20	4332-4338	normal	animal[227]	giv[227]	_	_
28-21	4339-4340	”	animal[227]	giv[227]	_	_
28-22	4341-4349	mitotane	animal[227]	giv[227]	_	_
28-23	4350-4364	concentrations	animal[227]	giv[227]	_	_
28-24	4365-4366	,	_	_	_	_
28-25	4367-4377	confirming	_	_	_	_
28-26	4378-4381	the	abstract[228]	new[228]	_	_
28-27	4382-4391	relevance	abstract[228]	new[228]	_	_
28-28	4392-4394	of	abstract[228]	new[228]	_	_
28-29	4395-4405	individual	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
28-30	4406-4413	factors	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
28-31	4414-4416	in	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
28-32	4417-4425	mitotane	abstract[228]|abstract[229]|abstract|abstract[231]	new[228]|giv[229]|giv|giv[231]	coref|coref	29-12|29-12
28-33	4426-4436	metabolism	abstract[228]|abstract[229]|abstract[231]	new[228]|giv[229]|giv[231]	_	_
28-34	4437-4438	.	_	_	_	_

#Text=Strengths of the present study are the thorough characterization of adjuvant mitotane treatment of ACC patients following surgical removal of the tumor and the large data set , considering the rarity of the disease .
29-1	4439-4448	Strengths	abstract[232]	new[232]	coref	29-7[234_232]
29-2	4449-4451	of	abstract[232]	new[232]	_	_
29-3	4452-4455	the	abstract[232]|abstract[233]	new[232]|giv[233]	coref	32-5[266_233]
29-4	4456-4463	present	abstract[232]|abstract[233]	new[232]|giv[233]	_	_
29-5	4464-4469	study	abstract[232]|abstract[233]	new[232]|giv[233]	_	_
29-6	4470-4473	are	_	_	_	_
29-7	4474-4477	the	abstract[234]	giv[234]	_	_
29-8	4478-4486	thorough	abstract[234]	giv[234]	_	_
29-9	4487-4503	characterization	abstract[234]	giv[234]	_	_
29-10	4504-4506	of	abstract[234]	giv[234]	_	_
29-11	4507-4515	adjuvant	abstract[234]|person|event[237]	giv[234]|giv|giv[237]	coref|coref	30-9[248_237]|30-9[248_237]
29-12	4516-4524	mitotane	abstract[234]|abstract|event[237]	giv[234]|giv|giv[237]	_	_
29-13	4525-4534	treatment	abstract[234]|event[237]	giv[234]|giv[237]	_	_
29-14	4535-4537	of	abstract[234]|event[237]	giv[234]|giv[237]	_	_
29-15	4538-4541	ACC	abstract[234]|event[237]|organization|person[239]	giv[234]|giv[237]|giv|giv[239]	coref|coref|coref|coref	31-21[0_239]|31-34|31-21[0_239]|31-34
29-16	4542-4550	patients	abstract[234]|event[237]|person[239]	giv[234]|giv[237]|giv[239]	_	_
29-17	4551-4560	following	_	_	_	_
29-18	4561-4569	surgical	event[240]	new[240]	ana	30-1[0_240]
29-19	4570-4577	removal	event[240]	new[240]	_	_
29-20	4578-4580	of	event[240]	new[240]	_	_
29-21	4581-4584	the	event[240]|object[241]	new[240]|new[241]	_	_
29-22	4585-4590	tumor	event[240]|object[241]	new[240]|new[241]	_	_
29-23	4591-4594	and	event[240]	new[240]	_	_
29-24	4595-4598	the	event[240]|abstract[242]	new[240]|new[242]	_	_
29-25	4599-4604	large	event[240]|abstract[242]	new[240]|new[242]	_	_
29-26	4605-4609	data	event[240]|abstract[242]	new[240]|new[242]	_	_
29-27	4610-4613	set	_	_	_	_
29-28	4614-4615	,	_	_	_	_
29-29	4616-4627	considering	_	_	_	_
29-30	4628-4631	the	abstract[243]	new[243]	_	_
29-31	4632-4638	rarity	abstract[243]	new[243]	_	_
29-32	4639-4641	of	abstract[243]	new[243]	_	_
29-33	4642-4645	the	abstract[243]|abstract[244]	new[243]|new[244]	_	_
29-34	4646-4653	disease	abstract[243]|abstract[244]	new[243]|new[244]	_	_
29-35	4654-4655	.	_	_	_	_

#Text=This allowed for the capture of details of mitotane treatment that were not available in previous studies and led to observations that may be useful to informing future practice .
30-1	4656-4660	This	event	giv	_	_
30-2	4661-4668	allowed	_	_	_	_
30-3	4669-4672	for	_	_	_	_
30-4	4673-4676	the	abstract[246]	new[246]	_	_
30-5	4677-4684	capture	abstract[246]	new[246]	_	_
30-6	4685-4687	of	abstract[246]	new[246]	_	_
30-7	4688-4695	details	abstract[246]|abstract[247]	new[246]|new[247]	_	_
30-8	4696-4698	of	abstract[246]|abstract[247]	new[246]|new[247]	_	_
30-9	4699-4707	mitotane	abstract[246]|abstract[247]|event[248]	new[246]|new[247]|giv[248]	coref	31-24[0_248]
30-10	4708-4717	treatment	abstract[246]|abstract[247]|event[248]	new[246]|new[247]|giv[248]	_	_
30-11	4718-4722	that	_	_	_	_
30-12	4723-4727	were	_	_	_	_
30-13	4728-4731	not	_	_	_	_
30-14	4732-4741	available	_	_	_	_
30-15	4742-4744	in	_	_	_	_
30-16	4745-4753	previous	abstract[249]	new[249]	_	_
30-17	4754-4761	studies	abstract[249]	new[249]	_	_
30-18	4762-4765	and	_	_	_	_
30-19	4766-4769	led	_	_	_	_
30-20	4770-4772	to	_	_	_	_
30-21	4773-4785	observations	abstract	new	_	_
30-22	4786-4790	that	_	_	_	_
30-23	4791-4794	may	_	_	_	_
30-24	4795-4797	be	_	_	_	_
30-25	4798-4804	useful	_	_	_	_
30-26	4805-4807	to	_	_	_	_
30-27	4808-4817	informing	_	_	_	_
30-28	4818-4824	future	abstract[251]	giv[251]	_	_
30-29	4825-4833	practice	abstract[251]	giv[251]	_	_
30-30	4834-4835	.	_	_	_	_

#Text=However , we should acknowledge the limits of a retrospective analysis , and that our results are not generalizable to patients who discontinue treatment within six months for intolerability or patients with early ACC recurrence .
31-1	4836-4843	However	_	_	_	_
31-2	4844-4845	,	_	_	_	_
31-3	4846-4848	we	person	giv	ana	31-15
31-4	4849-4855	should	_	_	_	_
31-5	4856-4867	acknowledge	_	_	_	_
31-6	4868-4871	the	abstract[253]	new[253]	_	_
31-7	4872-4878	limits	abstract[253]	new[253]	_	_
31-8	4879-4881	of	abstract[253]	new[253]	_	_
31-9	4882-4883	a	abstract[253]|abstract[254]	new[253]|giv[254]	_	_
31-10	4884-4897	retrospective	abstract[253]|abstract[254]	new[253]|giv[254]	_	_
31-11	4898-4906	analysis	abstract[253]|abstract[254]	new[253]|giv[254]	_	_
31-12	4907-4908	,	_	_	_	_
31-13	4909-4912	and	_	_	_	_
31-14	4913-4917	that	_	_	_	_
31-15	4918-4921	our	person|abstract[256]	giv|giv[256]	ana|ana	32-18|32-18
31-16	4922-4929	results	abstract[256]	giv[256]	_	_
31-17	4930-4933	are	_	_	_	_
31-18	4934-4937	not	_	_	_	_
31-19	4938-4951	generalizable	_	_	_	_
31-20	4952-4954	to	_	_	_	_
31-21	4955-4963	patients	person	giv	coref	31-31[261_0]
31-22	4964-4967	who	_	_	_	_
31-23	4968-4979	discontinue	_	_	_	_
31-24	4980-4989	treatment	event	giv	_	_
31-25	4990-4996	within	_	_	_	_
31-26	4997-5000	six	time[259]	giv[259]	coref	32-12[268_259]
31-27	5001-5007	months	time[259]	giv[259]	_	_
31-28	5008-5011	for	time[259]	giv[259]	_	_
31-29	5012-5026	intolerability	time[259]|abstract	giv[259]|new	_	_
31-30	5027-5029	or	time[259]	giv[259]	_	_
31-31	5030-5038	patients	time[259]|person[261]	giv[259]|giv[261]	_	_
31-32	5039-5043	with	time[259]|person[261]	giv[259]|giv[261]	_	_
31-33	5044-5049	early	time[259]|person[261]|abstract[263]	giv[259]|giv[261]|giv[263]	_	_
31-34	5050-5053	ACC	time[259]|person[261]|abstract|abstract[263]	giv[259]|giv[261]|giv|giv[263]	coref	32-25[272_0]
31-35	5054-5064	recurrence	time[259]|person[261]|abstract[263]	giv[259]|giv[261]|giv[263]	_	_
31-36	5065-5066	.	_	_	_	_

#Text=The inclusion criteria of the study produced an immortal time of six months that may have enriched our series of a higher number of low-risk ACC compared to recently published series .
32-1	5067-5070	The	abstract[265]	giv[265]	_	_
32-2	5071-5080	inclusion	person|abstract[265]	giv|giv[265]	_	_
32-3	5081-5089	criteria	abstract[265]	giv[265]	_	_
32-4	5090-5092	of	abstract[265]	giv[265]	_	_
32-5	5093-5096	the	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
32-6	5097-5102	study	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
32-7	5103-5111	produced	_	_	_	_
32-8	5112-5114	an	time[267]	new[267]	_	_
32-9	5115-5123	immortal	time[267]	new[267]	_	_
32-10	5124-5128	time	time[267]	new[267]	_	_
32-11	5129-5131	of	time[267]	new[267]	_	_
32-12	5132-5135	six	time[267]|time[268]	new[267]|giv[268]	_	_
32-13	5136-5142	months	time[267]|time[268]	new[267]|giv[268]	_	_
32-14	5143-5147	that	_	_	_	_
32-15	5148-5151	may	_	_	_	_
32-16	5152-5156	have	_	_	_	_
32-17	5157-5165	enriched	_	_	_	_
32-18	5166-5169	our	person|abstract[270]	giv|new[270]	coref|coref	32-29[273_270]|32-29[273_270]
32-19	5170-5176	series	abstract[270]	new[270]	_	_
32-20	5177-5179	of	abstract[270]	new[270]	_	_
32-21	5180-5181	a	abstract[270]|abstract[271]	new[270]|new[271]	_	_
32-22	5182-5188	higher	abstract[270]|abstract[271]	new[270]|new[271]	_	_
32-23	5189-5195	number	abstract[270]|abstract[271]	new[270]|new[271]	_	_
32-24	5196-5198	of	abstract[270]|abstract[271]	new[270]|new[271]	_	_
32-25	5199-5207	low-risk	abstract[270]|abstract[271]|abstract[272]	new[270]|new[271]|giv[272]	_	_
32-26	5208-5211	ACC	abstract[270]|abstract[271]|abstract[272]	new[270]|new[271]|giv[272]	_	_
32-27	5212-5220	compared	_	_	_	_
32-28	5221-5223	to	_	_	_	_
32-29	5224-5232	recently	abstract[273]	giv[273]	_	_
32-30	5233-5242	published	abstract[273]	giv[273]	_	_
32-31	5243-5249	series	abstract[273]	giv[273]	_	_
32-32	5250-5251	.	_	_	_	_
